 Myelodysplastic Syndromes
"Myelodysplastic Syndromes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.
| Descriptor ID |
D009190
|
| MeSH Number(s) |
C15.378.190.625
|
| Concept/Terms |
Myelodysplastic Syndromes- Myelodysplastic Syndromes
- Myelodysplastic Syndrome
- Syndrome, Myelodysplastic
- Syndromes, Myelodysplastic
- Dysmyelopoietic Syndromes
- Dysmyelopoietic Syndrome
- Syndrome, Dysmyelopoietic
- Syndromes, Dysmyelopoietic
Hematopoetic Myelodysplasia- Hematopoetic Myelodysplasia
- Hematopoetic Myelodysplasias
- Myelodysplasia, Hematopoetic
- Myelodysplasias, Hematopoetic
|
Below are MeSH descriptors whose meaning is more general than "Myelodysplastic Syndromes".
Below are MeSH descriptors whose meaning is more specific than "Myelodysplastic Syndromes".
This graph shows the total number of publications written about "Myelodysplastic Syndromes" by people in this website by year, and whether "Myelodysplastic Syndromes" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1986 | 3 | 0 | 3 | | 1988 | 1 | 0 | 1 | | 1989 | 2 | 0 | 2 | | 1990 | 1 | 0 | 1 | | 1992 | 3 | 1 | 4 | | 1993 | 5 | 3 | 8 | | 1994 | 1 | 0 | 1 | | 1995 | 2 | 1 | 3 | | 1996 | 8 | 0 | 8 | | 1997 | 5 | 2 | 7 | | 1998 | 0 | 1 | 1 | | 1999 | 1 | 2 | 3 | | 2000 | 5 | 1 | 6 | | 2001 | 2 | 0 | 2 | | 2002 | 9 | 1 | 10 | | 2003 | 3 | 2 | 5 | | 2004 | 2 | 1 | 3 | | 2005 | 5 | 2 | 7 | | 2006 | 3 | 0 | 3 | | 2007 | 4 | 2 | 6 | | 2008 | 2 | 1 | 3 | | 2009 | 10 | 4 | 14 | | 2010 | 3 | 1 | 4 | | 2011 | 6 | 1 | 7 | | 2012 | 7 | 1 | 8 | | 2013 | 8 | 1 | 9 | | 2014 | 9 | 1 | 10 | | 2015 | 10 | 0 | 10 | | 2016 | 9 | 4 | 13 | | 2017 | 11 | 2 | 13 | | 2018 | 7 | 1 | 8 | | 2019 | 6 | 0 | 6 | | 2020 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Myelodysplastic Syndromes" by people in Profiles.
-
Arber DA, Erba HP. Diagnosis and Treatment of Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Changes (AML-MRC). Am J Clin Pathol. 2020 11 04; 154(6):731-741.
-
Brown AL, Hahn C, Hiwase D, Godley LA, Scott HS. Correct application of variant classification guidelines in germline RUNX1 mutated disorders to assist clinical diagnosis. Leuk Lymphoma. 2020 01; 61(1):246-247.
-
Gurbuxani S. Lymphoblastic leukemia following MDS or MDS/MPN: clinical evidence for stem cell origins of these disorders. Leuk Lymphoma. 2019 12; 60(12):2847-2848.
-
Sundaravel S, Kuo WL, Jeong JJ, Choudhary GS, Gordon-Mitchell S, Liu H, Bhagat TD, McGraw KL, Gurbuxani S, List AF, Verma A, Wickrema A. Loss of Function of DOCK4 in Myelodysplastic Syndromes Stem Cells is Restored by Inhibitors of DOCK4 Signaling Networks. Clin Cancer Res. 2019 09 15; 25(18):5638-5649.
-
Garcia-Manero G, Roboz G, Walsh K, Kantarjian H, Ritchie E, Kropf P, O'Connell C, Tibes R, Lunin S, Rosenblat T, Yee K, Stock W, Griffiths E, Mace J, Podoltsev N, Berdeja J, Jabbour E, Issa JJ, Hao Y, Keer HN, Azab M, Savona MR. Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial. Lancet Haematol. 2019 Jun; 6(6):e317-e327.
-
Savona MR, Odenike O, Amrein PC, Steensma DP, DeZern AE, Michaelis LC, Faderl S, Harb W, Kantarjian H, Lowder J, Oganesian A, Azab M, Garcia-Manero G. An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study. Lancet Haematol. 2019 Apr; 6(4):e194-e203.
-
Churpek JE, Bresnick EH. Transcription factor mutations as a cause of familial myeloid neoplasms. J Clin Invest. 2019 02 01; 129(2):476-488.
-
Zhao B, Liu H, Mei Y, Liu Y, Han X, Yang J, Wickrema A, Ji P. Disruption of erythroid nuclear opening and histone release in myelodysplastic syndromes. Cancer Med. 2019 03; 8(3):1169-1174.
-
Calip GS, Moran KM, Sweiss KI, Patel PR, Wu Z, Adimadhyam S, Lee TA, Ko NY, Quigley JG, Chiu BC. Myelodysplastic syndrome and acute myeloid leukemia after receipt of granulocyte colony-stimulating factors in older patients with non-Hodgkin lymphoma. Cancer. 2019 04 01; 125(7):1143-1154.
-
Akpan IJ, Osman AEG, Drazer MW, Godley LA. Hereditary Myelodysplastic Syndrome and Acute Myeloid Leukemia: Diagnosis, Questions, and Controversies. Curr Hematol Malig Rep. 2018 12; 13(6):426-434.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|